Making a difference with your help.
Protocol Name: A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (Action3) Indication: Focal segmental glomerulosclerosis (FSGS) Primary Investigator: Dr. Kim Rice Location: 411 N Washington Ave, Suite 6000, Dallas, TX 75204 DETAILS >
Protocol Name: Otsuka Pharmaceutical Development & Commercialization, Inc. / “A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy” Indication: Immunoglobulin A Nephropathy Primary Investigator: Dr. Bernard Fischbach Location: Landry Office – 411 N. Washington Avenue, Suite 6000, Dallas, TX 75246 DETAILS >
Protocol Name: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS-IGAN). (Omeros) Indication: Immunoglobin nephropathy – IgA Primary Investigator: Dr. Akinwande Akinfolarin Location: 411 N Washington Ave, Suite 6000, Dallas, TX 75204 DETAILS >